Sienna Biopharmaceuticals, Inc. (NasdaqGS:SNNA) announced that it has retained Cowen Inc. (NasdaqGS:COWN) as an independent financial advisor to assist in exploring financial and strategic alternatives to maximize shareholder value. With Cowen's assistance, Sienna will continue to explore capital raising to enable the initiation of its planned Phase 3 pivotal clinical trials for SNA-120 (pegcantratinib), in addition to exploring a wide range of financial and strategic alternatives. No assurance can be given as to whether any particular financial or strategic alternative will be recommended or undertaken and, if so, upon what terms and conditions.